Evidence map›Paper›PMID 40067440›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Protective effects of pyridoxine, amlodipine, and their combination in a vasopressin-induced angina model in rats.

Mohammed A Al-Khawlani, Wafa M Al-Madhagi, Ahmed M Sabati, Saleh A M A ALomaisi, Maged Al-Najar

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Mohammed A Al-KhawlaniDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.
Wafa M Al-MadhagiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen. w.almadhagi@su.edu.ye.
Ahmed M SabatiDepartment of Pharmaceutics, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.
Saleh A M A ALomaisiDepartment of Anatomy and Embryology, Faculty of Veterinary Medicine, Sana'a University, Sana'a, Yemen.
Maged Al-NajarDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Malaya University, Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin B6 (pyridoxine) vitamins are of interest in preventative and protective strategies in cardiovascular disease. However, the safety and efficacy of vitamin B6 has been questioned. The aim of this study was to study the protective effect of pyridoxine, amlodipine, and their combination against vasopressin-induced angina model in rats. The administration of vasopressin (1 IU/kg, i.v.) to the rats elevated the S-wave level of the electrocardiogram reflecting the presence of subendocardial ischemia, whereas it decreased of the heart rate, resulting in the increase of the cardiac enzymes, creatine kinase MB (CK MB), and lactate dehydrogenase (LDH). In the vasopressin-induced angina model, oral administration of pyridoxine in dose of 5, 7, 10 mg/kg revealed dose-dependent suppression of vasopressin-triggered of ST elevation and in reduced of heart rat. In addition, pyridoxine produced dose-dependent suppression of cardiac enzymes, creatine kinase MB (CK MB), and lactate dehydrogenase (LDH) more than amlodipine and isosorbide; while in contrast, the combination of pyridoxine with amlodipine resulted in a trend towards increased adverse cardiovascular events; pyridoxine in dose 7 mg/kg was found to be more potent than pyridoxine in doses 5, 10 mg/kg, amlodipine and isosorbide on vasopressin-induced angina in rats. Pyridoxine in dose of (5, 7 mg) prevents cardiac necrosis and artery well thickened on vasopressin-induced angina modal. Pyridoxine's protective effects may be mediated by improved endothelial nitric oxide synthase (eNOS) function, reduction of homocysteine levels, and modulation of sympathetic activity. Pyridoxine at optimal doses shows promise as a novel therapeutic agent for coronary heart disease prevention, warranting further investigation into its potential clinical applications.

Indexed as

AmlodipineAngina PectorisPyridoxineAnimalsCreatine Kinase, MB FormDisease Models, AnimalDose-Response Relationship, DrugDrug Therapy, CombinationElectrocardiographyHeart RateL-Lactate DehydrogenaseMaleRatsRats, WistarVasopressinsAmlodipineCreatine Kinase, MB FormL-Lactate DehydrogenasePyridoxineVasopressinsAntianginalCardioprotectionECG changePyridoxineVasopressin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.